<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(1)</volume><submitter>Jang YC</submitter><pubmed_abstract>Hormone replacement therapy (HRT) is widely used to relieve menopausal symptoms; however, it remains unclear whether the use of HRT was associated with gastric cancer. We conducted a systematic review and meta-analysis to synthesize available evidence. This study followed the PRISMA guideline to report meta-analysis. PubMed, Embase, and Cochrane library were searched from conception through 23 February 2022. Eligible studies reporting risk of gastric cancer after HRT were screened and accessed by two independent reviewers. Random-effects meta-analysis was used to calculate pooled risk estimate as relative risk (RR, 95% CI). Pre-established review protocol was registered in PROSPERO (CRD42021281260). Among the 1095 articles identified, we included 11 studies with 1,919,089 women in this met</pubmed_abstract><journal>Scientific reports</journal><pagination>12997</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9338312</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Association of hormone replacement therapy with risk of gastric cancer: a systematic review and meta-analysis.</pubmed_title><pmcid>PMC9338312</pmcid><pubmed_authors>Leung CY</pubmed_authors><pubmed_authors>Huang HL</pubmed_authors><pubmed_authors>Jang YC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Association of hormone replacement therapy with risk of gastric cancer: a systematic review and meta-analysis.</name><description>Hormone replacement therapy (HRT) is widely used to relieve menopausal symptoms; however, it remains unclear whether the use of HRT was associated with gastric cancer. We conducted a systematic review and meta-analysis to synthesize available evidence. This study followed the PRISMA guideline to report meta-analysis. PubMed, Embase, and Cochrane library were searched from conception through 23 February 2022. Eligible studies reporting risk of gastric cancer after HRT were screened and accessed by two independent reviewers. Random-effects meta-analysis was used to calculate pooled risk estimate as relative risk (RR, 95% CI). Pre-established review protocol was registered in PROSPERO (CRD42021281260). Among the 1095 articles identified, we included 11 studies with 1,919,089 women in this met</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2025-04-22T03:29:15.141Z</modification><creation>2025-04-05T20:42:14.147Z</creation></dates><accession>S-EPMC9338312</accession><cross_references><pubmed>35906381</pubmed><doi>10.1038/s41598-022-17345-2</doi></cross_references></HashMap>